|
Allogene Therapeutics, Inc. (Allo) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Allogene Therapeutics, Inc. (ALLO) Bundle
¡Evalúe el espectáculo financiero de Allogene Therapeutics, Inc. (Allo) como un experto! Esta calculadora DCF (Allo) proporciona datos financieros preconidos junto con la flexibilidad para modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 38.5 | .2 | .1 | .1 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | -99.37 | -60.91 | -40.07 | -40.07 | -40.07 | -40.07 | -40.07 |
| EBITDA | -179.9 | -250.8 | -169.7 | -321.2 | -300.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | -441 | -132197.94 | -316097.89 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | 5.0 | 11.5 | 10.5 | 14.3 | 14.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 27.16 | 5882.72 | 14946.32 | 85.43 | 85.43 | 85.43 | 85.43 | 85.43 |
| EBIT | -184.9 | -262.3 | -180.2 | -335.5 | -314.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | -468.16 | -138080.66 | -331044.21 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 588.9 | 1,032.1 | 809.5 | 576.5 | 448.7 | .1 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .2 | .5 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | -60.7 | -207.0 | -20.0 | -62.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | -52.02 | -25700 | 0 | 9.6 | 9.6 | 9.6 | 9.6 | 9.6 |
| Accounts Payable | 9.3 | 10.4 | 10.3 | 13.9 | 5.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 26.64 | 5716.05 | 6207.37 | 85.33 | 85.33 | 85.33 | 85.33 | 85.33 |
| Capital Expenditure | -50.8 | -66.0 | -21.4 | -5.2 | -1.5 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | -55.72 | -2136.21 | -1595.79 | -51.14 | -51.14 | -51.14 | -51.14 | -51.14 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -184.6 | -244.8 | -171.7 | -332.7 | -314.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -162.8 | -149.4 | -369.8 | -277.5 | -372.3 | -5.9 | .0 | .0 | .0 | .0 |
| WACC, % | 7.54 | 7.48 | 7.49 | 7.53 | 7.54 | 7.52 | 7.52 | 7.52 | 7.52 | 7.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -5 | |||||||||
| Net Debt | 12 | |||||||||
| Equity Value | -17 | |||||||||
| Diluted Shares Outstanding, MM | 157 | |||||||||
| Equity Value Per Share | -0.11 |
What You Will Get
- Genuine Allogene Data: Preloaded financials – encompassing revenue to EBIT – derived from actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Updates: Automatic recalculations to assess the effects of changes on Allogene Therapeutics' fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and detailed forecasts.
- Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive Data: Allogene Therapeutics’ historical financial records and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Calculations: View Allogene Therapeutics’ intrinsic value update instantly.
- Visual Analytics: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based ALLO DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Allogene Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential valuation variations.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator for Allogene Therapeutics, Inc. (ALLO)?
- Accurate Data: Up-to-date Allogene financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential metrics like growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Ready-to-use calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.
Who Should Use Allogene Therapeutics, Inc. (ALLO)?
- Healthcare Investors: Make informed decisions with a cutting-edge biotechnology investment tool.
- Biotech Analysts: Streamline your analysis with a customizable model tailored for gene therapy insights.
- Consultants: Effortlessly modify the template for client discussions or strategic reports.
- Life Sciences Enthusiasts: Enhance your knowledge of innovative therapies using real-world case studies.
- Educators and Students: Utilize it as a hands-on resource in courses focused on biotechnology and healthcare.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Allogene Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Allogene Therapeutics, Inc. (ALLO).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.